publication date: Jun. 12, 2015

NCI Frederick Laboratory’s $400 Million Per Year Contract Up for Re-Competition



NCI is opening up its contract for operations and technical support at the Frederick National Laboratory for Cancer Research for re-competition—a process that officials said will take up to two years.

The institute is broadening the statement of work for the contract to maximize new opportunities in cancer research, which involves fostering interactions with academia. Bidders can include universities, consortia of universities, other nonprofit institutions and for-profit companies.

The contract, which was awarded in 2008, is scheduled to end in September 2018. Leidos Biomedical Research Inc. received $400.2 million to run the lab in fiscal 2014. It is not publicly known how much NCI is budgeting for the 2018 contract.

The lab, located on the 68-acre campus in Frederick, Md., is one of 41 Federally Funded Research and Development Centers. FFRDCs receive 70 percent or more of their financial support from the federal government.

The Frederick lab is operated by Leidos Biomedical Research—formerly known as SAIC-Frederick—the same contractor that has run the lab since 1995.

The Frederick campus, which includes the Advanced Technology Research Facility, a 330,000-square-foot complex with a biopharmaceutical development wing, is the only federally funded research center dedicated to biomedical research, specifically in the areas of cancer and other diseases.

NCI officials said the re-competition announcement, which was published on the Federal Business Opportunities website May … Continue reading 41-23 NCI Frederick Laboratory’s $400 Million Per Year Contract Up for Re-Competition

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.